Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

Astria Therapeutics (NASDAQ:ATXS), a biopharmaceutical company, announced that CEO Jill C. Milne, Ph.D., will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13 at 1:20 PM ET. The presentation will focus on the lead program STAR-0215, a monoclonal antibody being developed for hereditary angioedema. Investors can access a live webcast of the event at this link, with an archived replay available for 30 days on the company's website. Astria aims to provide life-changing therapies for rare allergic and immunological diseases.

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming virtual Oppenheimer 33^rd Annual Healthcare Conference on Monday, March 13^th at 1:20pm ET.

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/oppenheimer27/atxs/2819488. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005056/en/

Astria Contacts:



Investor relations:

Andrea Matthews

investors@astriatx.com



Media:

Elizabeth Higgins

media@astriatx.com

Source: Astria Therapeutics, Inc.

FAQ

What date will Astria Therapeutics present at the Oppenheimer conference?

Astria Therapeutics will present on March 13 at 1:20 PM ET.

What is STAR-0215 being developed for?

STAR-0215 is being developed for the treatment of hereditary angioedema.

Where can I access the webcast of Astria Therapeutics' presentation?

The webcast can be accessed at https://wsw.com/webcast/oppenheimer27/atxs/2819488.

How long will the archived presentation be available?

The archived presentation will be available for 30 days on the Astria Therapeutics website.

What is the focus of Astria Therapeutics?

Astria Therapeutics focuses on life-changing therapies for rare and niche allergic and immunological diseases.